NRx Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Benzinga

昨天

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) will release earnings for its first quarter before the opening bell on Monday, May 18.

Analysts expect the Wilmington, Delaware-based company to report quarterly loss of 11 cents per share, versus a loss of 34 cents per share in the year-ago period. The consensus estimate for NRx Pharmaceuticals' quarterly revenue is $19.43 million, according to Benzinga Pro.

On May 7, NRx Pharma received clearance from the FDA to initiate clinical trial of NRX-101 vs. placebo in patients with depression and suicidality.

NRx Pharmaceuticals shares gained 8.8% to close at $3.21 on Thursday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

D. Boral Capital analyst Jason Kolbert maintained a Buy rating with a price target of $34 on May 5, 2026. This analyst has an accuracy rate of 47%.
HC Wainwright & Co. analyst Patrick R. Trucchio maintained a Buy rating with a price target of $45 on April 27, 2026. This analyst has an accuracy rate of 69%.
Ascendiant Capital analyst Edward Woo maintained a Buy rating and increased the price target from $48 to $49 on April 27, 2026. This analyst has an accuracy rate of 46%.
BTIG analyst Thomas Shrader maintained a Buy rating with a price target of $25 on March 24, 2026. This analyst has an accuracy rate of 58%.

Considering buying NRXP stock? Here’s what analysts think:

Photo via Shutterstock

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2635083762"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2635083762\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2635083762?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-15 18:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635083762","market":"hk","top_or_hot":-1,"title":"NRx Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call","media":"Benzinga","content":"<html><body><p><strong>NRx Pharmaceuticals, Inc</strong>. (NASDAQ:NRXP) will release earnings for its first quarter before the opening bell on Monday, May 18.</p>\n<p>Analysts expect the Wilmington, <a href=\"https://laohu8.com/S/VMM\">Delaware</a>-based company to report quarterly loss of 11 cents per share, versus a loss of 34 cents per share in the year-ago period. The consensus estimate for NRx Pharmaceuticals' quarterly revenue is $19.43 million, according to Benzinga Pro.</p>\n<p>On May 7, NRx Pharma received clearance from the FDA to initiate clinical trial of NRX-101 vs. placebo in patients with depression and suicidality.</p>\n<p>NRx Pharmaceuticals shares gained 8.8% to close at $3.21 on Thursday.</p>\n<p>Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.</p>\n<p>Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.</p>\n<ul>\n<li>D. Boral Capital analyst Jason Kolbert maintained a Buy rating with a price target of $34 on May 5, 2026. This analyst has an accuracy rate of 47%.</li>\n<li>HC Wainwright &amp; Co. analyst Patrick R. Trucchio maintained a Buy rating with a price target of $45 on April 27, 2026. This analyst has an accuracy rate of 69%.</li>\n<li>Ascendiant Capital analyst Edward Woo maintained a Buy rating and increased the price target from $48 to $49 on April 27, 2026. This analyst has an accuracy rate of 46%.</li>\n<li>BTIG analyst Thomas Shrader maintained a Buy rating with a price target of $25 on March 24, 2026. This analyst has an accuracy rate of 58%.</li>\n</ul>\n<p>Considering buying NRXP stock? Here’s what analysts think: </p>\n<figure><img decoding=\"async\" height=\"462\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/15033236/image-405-1024x462.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/15033236/image-405-1024x462.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/15033236/image-405-300x135.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/15033236/image-405-768x346.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/15033236/image-405.png 1215w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NRx Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNRx Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2026-05-15 18:32</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<html><body><p><strong>NRx Pharmaceuticals, Inc</strong>. (NASDAQ:NRXP) will release earnings for its first quarter before the opening bell on Monday, May 18.</p>\n<p>Analysts expect the Wilmington, <a href=\"https://laohu8.com/S/VMM\">Delaware</a>-based company to report quarterly loss of 11 cents per share, versus a loss of 34 cents per share in the year-ago period. The consensus estimate for NRx Pharmaceuticals' quarterly revenue is $19.43 million, according to Benzinga Pro.</p>\n<p>On May 7, NRx Pharma received clearance from the FDA to initiate clinical trial of NRX-101 vs. placebo in patients with depression and suicidality.</p>\n<p>NRx Pharmaceuticals shares gained 8.8% to close at $3.21 on Thursday.</p>\n<p>Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.</p>\n<p>Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.</p>\n<ul>\n<li>D. Boral Capital analyst Jason Kolbert maintained a Buy rating with a price target of $34 on May 5, 2026. This analyst has an accuracy rate of 47%.</li>\n<li>HC Wainwright &amp; Co. analyst Patrick R. Trucchio maintained a Buy rating with a price target of $45 on April 27, 2026. This analyst has an accuracy rate of 69%.</li>\n<li>Ascendiant Capital analyst Edward Woo maintained a Buy rating and increased the price target from $48 to $49 on April 27, 2026. This analyst has an accuracy rate of 46%.</li>\n<li>BTIG analyst Thomas Shrader maintained a Buy rating with a price target of $25 on March 24, 2026. This analyst has an accuracy rate of 58%.</li>\n</ul>\n<p>Considering buying NRXP stock? Here’s what analysts think: </p>\n<figure><img decoding=\"async\" height=\"462\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/15033236/image-405-1024x462.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/15033236/image-405-1024x462.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/15033236/image-405-300x135.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/15033236/image-405-768x346.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/05/15033236/image-405.png 1215w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/05/52590777/nrx-pharmaceuticals-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call","article_id":"2635083762","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635083762","pubTimestamp":1778841127,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"NRx Pharma (NRXP) set to release Q1 earnings on May 18. Analysts expect $19.43 million in revenue, with a loss of 11 cents per share. FDA clearance received for clinical trial.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","NRXP":"NRX Pharmaceuticals Inc."},"translate_title":"NRx Pharmaceuticals盈利迫在眉睫；这些最准确的分析师在收益看涨期权之前修改了预测","themeId":"11c8fbbf839f433c9d274cef5f173382","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRXP":1},"content_text":"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) will release earnings for its first quarter before the opening bell on Monday, May 18.\nAnalysts expect the Wilmington, Delaware-based company to report quarterly loss of 11 cents per share, versus a loss of 34 cents per share in the year-ago period. The consensus estimate for NRx Pharmaceuticals' quarterly revenue is $19.43 million, according to Benzinga Pro.\nOn May 7, NRx Pharma received clearance from the FDA to initiate clinical trial of NRX-101 vs. placebo in patients with depression and suicidality.\nNRx Pharmaceuticals shares gained 8.8% to close at $3.21 on Thursday.\nBenzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.\nLet's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.\n\nD. Boral Capital analyst Jason Kolbert maintained a Buy rating with a price target of $34 on May 5, 2026. This analyst has an accuracy rate of 47%.\nHC Wainwright & Co. analyst Patrick R. Trucchio maintained a Buy rating with a price target of $45 on April 27, 2026. This analyst has an accuracy rate of 69%.\nAscendiant Capital analyst Edward Woo maintained a Buy rating and increased the price target from $48 to $49 on April 27, 2026. This analyst has an accuracy rate of 46%.\nBTIG analyst Thomas Shrader maintained a Buy rating with a price target of $25 on March 24, 2026. This analyst has an accuracy rate of 58%.\n\nConsidering buying NRXP stock? Here’s what analysts think: \n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}